Data Entry: Please note that the research database will be replaced by UNIverse by the end of October 2023. Please enter your data into the system https://universe-intern.unibas.ch. Thanks
Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer : the BIG 1-98 randomised clinical trial at 8·1 years median follow-up
JournalArticle (Originalarbeit in einer wissenschaftlichen Zeitschrift)
ID
1196819
Author(s)
Regan, Meredith M; Neven, Patrick; Giobbie-Hurder, Anita; Goldhirsch, Aron; Ejlertsen, Bent; Mauriac, Louis; Forbes, John F; Smith, Ian; Láng, István; Wardley, Andrew; Rabaglio, Manuela; Price, Karen N; Gelber, Richard D; Coates, Alan S; Thürlimann, Beat; BIG 1-98 Collaborative Group; International Breast Cancer Study Group (IBCSG)
Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer : the BIG 1-98 randomised clinical trial at 8·1 years median follow-up
Journal
The Lancet oncology
Volume
12
Number
12
Pages / Article-Number
1101-8
Abstract
Postmenopausal women with hormone receptor-positive early breast cancer have persistent, long-term risk of breast-cancer recurrence and death. Therefore, trials assessing endocrine therapies for this patient population need extended follow-up. We present an update of efficacy outcomes in the Breast International Group (BIG) 1-98 study at 8·1 years median follow-up.
